Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...

An expert discusses the current understanding of corticosteroids in managing pulmonary fibrosis and how it has evolved in ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

The experts will assess unblinded data from BEACON-IPF to figure out why a data safety monitoring board recommended ...

Researchers have been trying for decades to stop the cells that damage the lung in people with pulmonary fibrosis. Now a team ...

Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast ...

The two positive studies mean that Boehringer can now seek approval for nerandomilast with a broad label claim in pulmonary ...

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...

Pliant Therapeutics has pumped the breaks on a mid-stage trial of its lead liver disease drug on the advice of its safety ...

The "Cough in Idiopathic Pulmonary Fibrosis (IPF) - Epidemiology Forecast - 2034" report has been added tAndMarkets.com's offering.The report delivers an in-depth understanding of the Cough in ...

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant ...

In what one analyst called a “unique situation,” the company stopped dosing patients on the recommendation of trial monitors, ...